Oncotelic Therapeutics 2025 10-K: Net income $249.02M; EPS $0.59
I'm LongbridgeAI, I can summarize articles.Oncotelic Therapeutics reported a net income of $249.02 million for 2025, primarily due to a fair value gain on its GMP Bio investment. The company had a loss from operations of $3.19 million, an improvement from the previous year. Net income before taxes was $360.57 million, largely from a $365.35 million fair value change. The joint venture with GMP Bio advanced OT-101 development and is pursuing a Hong Kong IPO. The company also expanded its nanoparticle platform and integrated AI for biomarker discovery.
Oncotelic Therapeutics reported a net income of $249.02 million for the year ended December 31, 2025, driven primarily by a fair value gain on its investment in GMP Bio; diluted and basic earnings per share were $0.59. The company recorded a loss from operations of $3.19 million for 2025, an improvement versus the prior year. Net income before taxes reflected a $360.57 million figure attributable largely to a $365.35 million fair value change in the GMP Bio investment.
Financial Highlights
- Operating Income: $(3.19) million loss from operations for year ended Dec 31, 2025 (improved $0.39M vs 2024).
- Net Income (Loss) before income taxes: $360.57 million, reflecting a $365.35 million change in fair value of the investment in GMP Bio.
- Net Income: $249.02 million for year ended Dec 31, 2025 (compared with $(4.78) million in 2024), driven by fair value gain.
- Net income attributable to Oncotelic Therapeutics: $249.28 million after adjustments for non-controlling interest.
- Net Income Per Share: $0.59 basic and diluted for year ended Dec 31, 2025.
Business Highlights
- Joint Venture Progress: GMP Bio joint venture advanced OT-101 development, completed a Phase 1 OT-101 plus IL-2 trial and initiated studies in pancreatic cancer, non-small cell lung cancer, and mesothelioma.
- Valuation & Strategic Plans: The joint venture obtained an independent pipeline valuation of $2.3 billion and is pursuing a Hong Kong IPO alongside third-party financing to scale operations.
- Nanoparticle Platform & Manufacturing: The Nano/Deciparticle platform expanded to support multiple oncology candidates and the GMP San Diego facility is licensed for drug manufacturing.
- AI & Automation Integration: The PDAOAI matured into a TGF-β knowledge platform for biomarker discovery and the company partnered with TechForce to commercialize GMP robotics.
Original SEC Filing: Oncotelic Therapeutics, Inc. [ OTLC ] - 10-K - Apr. 15, 2026